RxDoctor Payments DataLook up a doctor →

Kelsey Sturgis, PA

General Practice · Grand Rapids, MINPI 1306235569

Payments from drug & device makers

$8,554in general payments, 2019–2025

Across 466 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$598
  • E.r. Squibb & Sons, L.L.C.$572
  • Boehringer Ingelheim$557
  • AstraZeneca$497
  • Pfizer$478
  • GSK$446
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$8,554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,554 in reported general payments places this provider in the 95th percentile of 3,051 general practice providers in Michigan.

See all general practice providers in Michigan

Medicare billing

Part B allowed, 2024
$51,188
Medicare patients
235
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$111,616
MounjaroTirzepatide45$44,860
JardianceEmpagliflozin31$44,210
XareltoRivaroxaban24$30,193
EntrestoSacubitril/Valsartan24$24,356
TrulicityDulaglutide20$24,341
MyrbetriqMirabegron18$14,209
Repatha SureclickEvolocumab17$11,306
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,586
Rosuvastatin Calcium111$2,780
Atorvastatin Calcium165$2,648
Metoprolol Succinate98$2,444
Levothyroxine Sodium107$2,071
Losartan Potassium110$1,841
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$478$113,029117 claims
Lilly USA, LLCMounjaro, Trulicity$347$69,20165 claims
Boehringer IngelheimJardiance$557$44,21031 claims
Johnson & JohnsonXarelto$407$30,19324 claims
NovartisEntresto$385$24,35624 claims
Astellas Pharma US IncMyrbetriq$269$14,20918 claims
GSKTrelegy Ellipta$446$8,58614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,051 general practice providers in Michigan.

Other general practice in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →